IL4/IL13 are the central cytokines for type 2 inflammation in CRSwNP
Dupixent has rapid and sustained efficacy in CRSwNP with more than 50% reduction in mean Nasal congestion.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-kw/Article-Images/images/jcr_content-(11).jpg0/jcr:content/jcr_content%20(11).jpg)
Related articles
MAT-BH-2201023/V1/FEB2023
Dupixent has rapid and sustained efficacy in CRSwNP with more than 50% reduction in mean Nasal congestion.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.